1 Biotech Stock Set to Rebound in 2026
Key Points
This weight-loss leader was drubbed last year.
It's a popular pick as a 2026 rebound candidate.
More than that popularity, it has credible catalysts to bounce back this year.
- 10 stocks we like better than Novo Nordisk ›
For all the enthusiasm around GLP-1s, also known as weight-loss drugs, Novo Nordisk (NYSE: NVO) tumbled nearly 42% in 2025. The once hot stock was confounded by headwinds, including rivals making progress in the weight-loss arena and the emergence of cheaper generics.
Fast-forward to 2026, and the stock is already shedding last year's bear market conditions. Shares of the maker of Wegovy are up 25% year to date. That's a new bull market and then some.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
This weight-loss leader is already rebounding and could extend that bullishness this yea. Image source: Getty Images
A 25% rally in three weeks prompts investors to wonder if they've missed the "easy money," but there are reasons to believe Novo Nordisk's gains could be built upon as 2026 moves forward.
Wegovy has pill power
The earliest GLP-1 formulations were administered by injection. That's not a big deal for many patients, but there are still plenty of us who have unpleasant memories of childhood visits to the doctor's office involving needles. Sounds folksy, but it underscores why the FDA approval of a Wegovy pill earlier this month is significant for Novo Nordisk shares.
Bank of America estimates Novo Nordisk needs to move 2,000 prescriptions per week to achieve 2026 sales targets. Recent data from Symphony Health indicate prescriptions for the oral version of Wegovy surged to 20,392 last week, more than quadruple the prior week's rate.
While it's clear the Wegovy pill is popular with patients, it's not cannibalizing the injectable version, with data indicating prescriptions for that form of the GLP-1 are holding steady.
The pill can also expand the avenues through which Novo Nordisk can shop this offering. More telehealth providers, including Amazon Pharmacy and LifeMD, are offering the pill, making it easier for patients to access it without going to a doctor's office.
Currently, the U.S. is the only country where the Wegovy pill is available. If more countries join the club, that could spark a rally in Novo Nordisk stock. The potential for those approvals is there. For example, Great Britain's pharmaceuticals regulator is examining the Wegovy pill. Other regions where the injectable version is legal could also make for logical adopters of the oral version.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $462,174!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,143,099!*
Now, it’s worth noting Stock Advisor’s total average return is 946% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of January 28, 2026.
Todd Shriber has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
